[go: up one dir, main page]

EP2809662A4 - INHIBITORS OF RIBONUCLEOTIDE REDUCTASE AND METHODS OF USE - Google Patents

INHIBITORS OF RIBONUCLEOTIDE REDUCTASE AND METHODS OF USE

Info

Publication number
EP2809662A4
EP2809662A4 EP13743552.5A EP13743552A EP2809662A4 EP 2809662 A4 EP2809662 A4 EP 2809662A4 EP 13743552 A EP13743552 A EP 13743552A EP 2809662 A4 EP2809662 A4 EP 2809662A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
methods
ribonucleotide reductase
ribonucleotide
reductase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13743552.5A
Other languages
German (de)
French (fr)
Other versions
EP2809662A1 (en
EP2809662B1 (en
Inventor
David Horne
Christopher Lincoln
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/364,263 external-priority patent/US8372983B2/en
Application filed by City of Hope filed Critical City of Hope
Publication of EP2809662A1 publication Critical patent/EP2809662A1/en
Publication of EP2809662A4 publication Critical patent/EP2809662A4/en
Application granted granted Critical
Publication of EP2809662B1 publication Critical patent/EP2809662B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EP13743552.5A 2012-02-01 2013-02-01 Ribonucleotide reductase inhibitors and methods of use Active EP2809662B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/364,263 US8372983B2 (en) 2008-04-08 2012-02-01 Ribonucleotide reductase inhibitors and methods of use
PCT/US2013/024490 WO2013116765A1 (en) 2012-02-01 2013-02-01 Ribonucleotide reductase inhibitors and methods of use

Publications (3)

Publication Number Publication Date
EP2809662A1 EP2809662A1 (en) 2014-12-10
EP2809662A4 true EP2809662A4 (en) 2015-07-29
EP2809662B1 EP2809662B1 (en) 2018-07-04

Family

ID=48905915

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13743552.5A Active EP2809662B1 (en) 2012-02-01 2013-02-01 Ribonucleotide reductase inhibitors and methods of use

Country Status (8)

Country Link
US (5) US9126960B2 (en)
EP (1) EP2809662B1 (en)
JP (1) JP6038184B2 (en)
CN (2) CN104136423B (en)
AU (1) AU2013214846B2 (en)
CA (1) CA2862704C (en)
ES (1) ES2681027T3 (en)
WO (1) WO2013116765A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136423B (en) 2012-02-01 2019-03-08 希望之城 Ribonucleotide reductase inhibitors and methods of use
CN104418821A (en) * 2013-08-22 2015-03-18 四川大学华西医院 2, 4-substituted 5- (3,4, 5-trimethoxyphenyl) thiazole derivative and preparation method and application thereof
JP6473461B2 (en) * 2014-03-26 2019-02-20 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Treatment of BRCA1-deficient or resistant cancer
EP3303339B1 (en) 2015-07-07 2021-01-13 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
CN108431224B (en) * 2015-09-01 2020-01-17 苏州瑞博生物技术有限公司 Small interfering nucleic acid, pharmaceutical composition and application thereof
AU2018215792A1 (en) * 2017-02-06 2019-09-26 City Of Hope Treatment of cancer
KR20210014662A (en) 2018-05-25 2021-02-09 이마라 인크. 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1, 5-a]Pyrazin-8-one monohydrate and crystalline form
CN108794328A (en) * 2018-08-03 2018-11-13 上海华堇生物技术有限责任公司 The preparation method of 3,4- dimethoxy-benzoyl chlorides
EP3843737A4 (en) 2018-08-31 2022-06-01 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258915A1 (en) * 2008-04-08 2009-10-15 Yun Yen Ribonucleotide reductase inhibitors and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2206315A1 (en) * 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
DE60128661D1 (en) * 2000-03-01 2007-07-12 Scripps Research Inst NINGALIN B ANALOGA SUITABLE FOR THE ABOLITION OF MULTI-MEDICATION RESISTANCE
CA2520957C (en) 2003-03-31 2013-08-06 Sucampo Ag Method for treating vascular hyperpermeable disease
CN101096363B (en) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-three-substituted thiazole compound, preparation method, medicament composition and pharmacy use thereof
USRE45020E1 (en) * 2008-04-08 2014-07-15 City Of Hope Ribonucleotide reductase inhibitors and methods of use
US8372983B2 (en) 2008-04-08 2013-02-12 City Of Hope Ribonucleotide reductase inhibitors and methods of use
EP2547676B1 (en) * 2010-03-17 2015-07-29 Taivex Therapeutics Inc. Modulators of hec1 activity and methods therefor
CN101885709A (en) * 2010-06-24 2010-11-17 海门慧聚药业有限公司 Novel thiazolamine compound and synthesis thereof
CN102070555A (en) * 2011-01-13 2011-05-25 山东齐都药业有限公司 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazoline-2,4-diketone and derivatives thereof
CN104136423B (en) * 2012-02-01 2019-03-08 希望之城 Ribonucleotide reductase inhibitors and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258915A1 (en) * 2008-04-08 2009-10-15 Yun Yen Ribonucleotide reductase inhibitors and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETER G M WUTS ET AL: "PROTECTION FOR PHENOLS AND CATECHOLS PROTECTION FOR PHENOLS 370 Ethers 370 Methyl", GREENE'S PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, FOURTH EDITION, 10 April 2006 (2006-04-10), pages 367 - 430, XP055196484, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1002/9780470053485.ch3/pdf> [retrieved on 20150617] *
See also references of WO2013116765A1 *

Also Published As

Publication number Publication date
EP2809662A1 (en) 2014-12-10
WO2013116765A1 (en) 2013-08-08
EP2809662B1 (en) 2018-07-04
ES2681027T3 (en) 2018-09-11
JP6038184B2 (en) 2016-12-07
US10155732B2 (en) 2018-12-18
CN104136423B (en) 2019-03-08
US20190161461A1 (en) 2019-05-30
US9796692B2 (en) 2017-10-24
US20150087844A1 (en) 2015-03-26
AU2013214846B2 (en) 2017-09-07
US20180155303A1 (en) 2018-06-07
CA2862704A1 (en) 2013-08-08
JP2015505566A (en) 2015-02-23
US9598385B2 (en) 2017-03-21
CN104136423A (en) 2014-11-05
AU2013214846A1 (en) 2014-08-14
CN108658892A (en) 2018-10-16
CA2862704C (en) 2021-01-05
US20160122308A1 (en) 2016-05-05
US9126960B2 (en) 2015-09-08
US20170137392A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
EP2912178A4 (en) SUPER-ACTIVATORS AND METHODS OF USE THEREOF
EP2849788A4 (en) METHODS AND USE OF SUBTILISINE / KEXINE 9 PROPYTEIN CONVERTASE INHIBITORS (PCSK9)
EP2812355A4 (en) COMPOSITIONS AND METHODS OF USING CSF1R INHIBITORS
EP2619184A4 (en) DEUBIQUITINASE INHIBITORS AND METHODS OF USE
EP2776038A4 (en) ACC INHIBITORS AND USES THEREOF
EP2673381A4 (en) BIOSONS AND METHODS OF USE THEREOF
EP2920319A4 (en) SITE SPECIFIC ENZYMES AND METHODS OF USE THEREOF
EP2670866A4 (en) BIOMARKERS AND METHODS OF USE
EP2773651A4 (en) SPECIFIC B7-H4-ISOLATED COMPOSITIONS AND METHODS OF USE THEREOF
EP2809662A4 (en) INHIBITORS OF RIBONUCLEOTIDE REDUCTASE AND METHODS OF USE
HK1213769A1 (en) Arginase inhibitors and methods of use thereof
EP2964651A4 (en) BMP INHIBITORS AND METHODS OF USE
EP2763597A4 (en) SUTURE ANCHORS AND METHODS OF USE
EP2788370A4 (en) MODIFIED MINI-HEPCIDINE PEPTIDES AND METHODS OF USE
EP2970311A4 (en) BMP INHIBITORS AND METHODS OF USE
EP2882750A4 (en) DOT1L PROTEIN METHYLTRANSFERASE INHIBITORS AND METHODS OF USE
EP2914575A4 (en) INHIBITORS OF PLASMINOGEN ACTIVATOR 1 AND METHODS OF USE
EP2579831A4 (en) DISTRIBUTOR AND METHODS OF USE
EP2670733A4 (en) HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
HK1179636A1 (en) Antibody and method of use
LT2909204T (en) Gsk3 inhibitors and methods of use thereof
EP2766393A4 (en) ANTI-HTRA1 ANTIBODIES AND METHODS OF USE
EP2735142A4 (en) USE OF AN ARTICLE
EP2833879A4 (en) KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
EP2667889A4 (en) WNT COMPOSITIONS AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150625

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/426 20060101ALI20150619BHEP

Ipc: C07D 277/46 20060101AFI20150619BHEP

Ipc: A61P 35/00 20060101ALI20150619BHEP

17Q First examination report despatched

Effective date: 20160607

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20171214

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CITY OF HOPE

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

INTG Intention to grant announced

Effective date: 20180529

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1014365

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013039723

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2681027

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180911

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180704

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1014365

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181104

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181005

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181004

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181004

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013039723

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

26N No opposition filed

Effective date: 20190405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190201

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190228

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181105

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180704

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240301

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240228

Year of fee payment: 12

Ref country code: GB

Payment date: 20240227

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240222

Year of fee payment: 12

Ref country code: FR

Payment date: 20240226

Year of fee payment: 12